额叶侵犯的嗅神经母细胞瘤患者的治疗结果
The Treatment Outcomes of Olfactory Neuroblastoma Patients With Frontal Lobe Invasion.
作者信息
Wang Jie, Wang Li, He Huanyu, Li Yi, Song Xinmao
机构信息
Department of Radiation Oncology, Eye, Ear, Nose & Throat Hospital of Fudan University, Shanghai, China.
Department of Oncology, 920th Hospital of Joint Logistics Support Force, Kunming, China.
出版信息
Front Oncol. 2021 Jul 5;11:640892. doi: 10.3389/fonc.2021.640892. eCollection 2021.
BACKGROUND
To investigate whether frontal lobe invasion (FLI) was an unfavorable prognostic factor in patients with olfactory neuroblastoma (ONB), and to explore the optimal treatment strategy for ONB patients with FLI.
METHODS
Some 37 patients with FLI were retrospectively studied, and 74 well-matched patients without FLI were enrolled as the control group. The long-term survivals were compared between the two groups.
RESULTS
No significant differences were found between the two groups in overall survival (OS), progression-free survival (PFS), locoregional failure-free survival (LRFS), and distant metastasis-free survival (DMFS) (all p >0.05). Multivariate analyses showed that FLI wasn't an independent predictor for OS (HR = 1.100, 95% CI = 0.437-2.772, p = 0.840). Among the 37 patients with FLI, patients who received surgery combined with chemo-/radiotherapy showed better OS (89.4% 53.6%, p = 0.001) and PFS (87.8% 53.6%, p = 0.001) compared with those who didn't undergo surgery.
CONCLUSIONS
FLI wasn't a poor prognostic factor for ONB patients. Endoscopic resection combined with radiotherapy was an effective therapeutic method for ONB patients with FLI.
背景
探讨额叶侵犯（FLI）是否为嗅神经母细胞瘤（ONB）患者的不良预后因素，并探索ONB伴FLI患者的最佳治疗策略。
方法
回顾性研究37例FLI患者，并纳入74例匹配良好的无FLI患者作为对照组。比较两组的长期生存率。
结果
两组在总生存期（OS）、无进展生存期（PFS）、局部区域无复发生存期（LRFS）和远处转移无复发生存期（DMFS）方面均无显著差异（所有p>0.05）。多因素分析显示，FLI不是OS的独立预测因素（HR = 1.100，95%CI = 0.437 - 2.772，p = 0.840）。在37例FLI患者中，接受手术联合放化疗的患者与未接受手术的患者相比，OS（89.4%对53.6%，p = 0.001）和PFS（87.8%对53.6%，p = 0.001）更好。
结论
FLI不是ONB患者的不良预后因素。内镜切除联合放疗是ONB伴FLI患者的有效治疗方法。
Zotero 插件